JCN Newswire4h
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate
Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China ...
JCN Newswire5h
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC
SHANGHAI, Nov 30, 2024 - (ACN Newswire) - Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which ...
JCN Newswire5h
華領醫藥宣佈成功完成在中國香港開展的SENSITIZE研究
華領醫藥（「本公司」）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥匯聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和產品，引領全球糖尿病醫療創新。公司核心產品華堂寧 ...
JCN Newswire5h
华领医药宣布成功完成在中国香港开展的SENSITIZE研究
华领医药（"本公司"）是一家总部位于中国上海的创新药物研发和商业化公司，在美国、中国香港设立了公司。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。公司核心产品华堂宁（R）（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖 ...